Companies
Saturday, 6/27, 07:43 PM
AbbVie to Buy Apogee Therapeutics for $10.9 Billion in an Immunology Bet
- AbbVie agreed to acquire the biotech Apogee Therapeutics for $135.11 a share in cash — about $10.9 billion — its biggest deal since buying Allergan in 2019, as the drugmaker scrambles to build new revenue to replace its fading blockbuster Humira.